The EVOLUTION HF study aimed to report real-world characteristics and treatment patterns in patients who received dapagliflozin following hospitalized heart failure, an area with minimal clinical data. In this touchCARDIO interview, we speak with Dr Gianluigi Savarese (Karolinska University Hospital, Stockholm, Sweden) to discuss the limitations of current guideline-directed medical therapies in patients with heart failure (HF) with reduced ejection fraction (HFrEF)aims and findings of the EVOLUTION HF study
The abstract entitled ‘Dapagliflozin utilization following hospitalization for heart failure: real-world insights from EVOLUTION HF, a multinational, observational study’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
- What are the limitations of current guideline-directed medical therapies in patients with heart failure (HF) with reduced ejection fraction (HFrEF)? (0:35)
- What is known about the impact of dapagliflozin on HF outcomes in patients with HFrEF? (1:26)
- What were the aims and design of the EVOLUTION HF study? (2:56)
- What did the study teach us about dapagliflozin utilization following hospitalization for heart failure? (3:46)
- What is the key take home message of these findings? (4:53)
Disclosures: The study has been supported by AstraZeneca.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Heart Failure here
Share this Video
Related Videos In Heart Failure
Divaka Perera, ESC 2022: Percutaneous revascularisation in patients with severe ischaemic cardiomyopathy, the REVIVED trial
The REVIVED study aimed to assess whether the addition of stents when treating patients with severe ischaemic cardiomyopathy would be beneficial to patient outcomes. In this touchCARDIO interview, we speak with Professor Divaka Perera (King’s College London, London, UK) to discuss the REVIVED trial, its outcomes and how they will affect the current treatment paradigm. […]
Divaka Perera, ESC 2022: The unmet needs in patients with heart failure due to ischaemic cardiomyopathy
In an ideal scenario, patients with ischaemic cardiomyopathy would receive specific treatment options beyond the general heart failure management currently in place. In this touchCARDIO interview, we speak with Professor Divaka Perera (King’s College London, London, UK) to discuss the unmet needs in this population and give an evaluation of surgical and percutaneous revascularization in […]
Caroline Sindet-Pedersen, ESC 2022: SARS-CoV-2 mRNA vaccines in patients with heart failure
Studies investigating the safety and efficacy of the severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2) mRNA vaccines lacked representation of patients with heart failure. In this touchCARDIO interview, we speak with Dr Caroline Sindet-Pedersen (Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark) to discuss the study presented at ESC 2022 that aimed to investigate […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!